2026. Selecting the Optimal Treatment Line for CDK4/6 Inhibitors in Hormone Receptor-Positive, HER2-Negative Breast Cancer. Voprosy onkologii. 72, 3 (Jul. 2026), OF-2455. DOI:https://doi.org/10.37469/0507-3758-2026-72-3-OF-2455.